ABSTRACT
Objective:
To study the effect of pidotimod combined with montelukast
sodium in the
treatment of
patients with
asthma, and its influence on the levels of inflammatory factors and immune function.
Methods:
From February 2019 to February 2020, 102
patients with
bronchial asthma admitted to Zhuji People's
Hospital were randomly divided into the
observation group and the
control group, with 51 cases in each group.The
control group was treated with montelukast
sodium, and the
observation group was given pidotimod combined with montelukast
sodium.The clinical effect,
lung function index, inflammatory factors,
T lymphocyte subsets and the
incidence of adverse reactions were compared between the two groups.
Results:
The total effective rate of the
observation group was 90.20%(46/51), which was higher than that of the
control group [74.51%(38/51)](χ 2=4.317, P=0.038).
After treatment, FEV 1, FVC, PEF in the
observation group were (82.89±6.94)%, (3.89±0.45)L, (3.49±0.49)L/s, respectively, which were higher than those in the
control group [(77.89±6.79)%, (3.58±0.43)L, (3.21±0.45)L/s] ( t=7.370, 5.753, 4.239, all P<0.05).
After treatment, the
serum levels of
procalcitonin (PCT),
interleukin-6 (
IL-6),
C-reactive protein (CRP) in the
observation group were (1.45±0.49)μg/L, (9.87±2.65)mg/L, (5.79±1.48)mg/L, respectively, which were lower than those in the
control group [(1.79±0.55)μg/L, (12.34±2.97)mg/L, (7.23±1.68)mg/L] ( t=4.624, 6.542, 8.090, all P<0.05).
After treatment, the CD 3+ , CD 4+ , CD 4+ /CD 8+ in the
observation group were (53.43±5.43)%, (46.34±5.31)%, (1.54±0.23), respectively, which were higher than those in the
control group [(48.09±5.17)%, (41.89±5.15)%, (1.26±0.22)], while the CD 8+ in the
observation group[(30.65±3.54)%] was lower than that in the
control group[(33.72±3.69)%], the differences were statistically significant ( t=3.901, 4.080, 4.072, 5.967, all P<0.05). During the
treatment period, the
incidences of adverse reactions in the
observation group and the
control group were 15.69%(8/51) and 9.80%(5/51), respectively, there was no statistically significant difference between the two groups (χ 2=0.793, P=0.373).
Conclusion:
Pidotimod combined with montelukast
sodium has significant
therapeutic effect on
bronchial asthma.It can improve the pulmonary function, reduce the levels of inflammatory factors, improve the immune function of the body, and has good
therapeutic safety.It has a high clinical application value.